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The Journal of Immunology
Comparison of Heterosubtypic Protection in Ferrets and Pigs
Induced by a Single-Cycle Influenza Vaccine
Barbara Holzer,*,1 Sophie B. Morgan,*,1 Yumi Matsuoka,†,1 Matthew Edmans,*
Francisco J. Salguero,‡ Helen Everett,x Sharon M. Brookes,x Emily Porter,{
Ronan MacLoughlin,‖ Bryan Charleston,* Kanta Subbarao,†,2 Alain Townsend,# and
Elma Tchilian*
Influenza is a major health threat, and a broadly protective influenza vaccine would be a significant advance. Signal Minus FLU
(S-FLU) is a candidate broadly protective influenza vaccine that is limited to a single cycle of replication, which induces a strong
cross-reactive T cell response but a minimal Ab response to hemagglutinin after intranasal or aerosol administration. We tested
whether an H3N2 S-FLU can protect pigs and ferrets from heterosubtypic H1N1 influenza challenge. Aerosol administration of
S-FLU to pigs induced lung tissue-resident memory T cells and reduced lung pathology but not the viral load. In contrast, in
ferrets, S-FLU reduced viral replication and aerosol transmission. Our data show that S-FLU has different protective efficacy in
pigs and ferrets, and that in the absence of Ab, lung T cell immunity can reduce disease severity without reducing challenge viral
replication. The Journal of Immunology, 2018, 200: 000–000.
I
nfluenza virus infection is a global health threat to livestock
and humans, causing substantial mortality. The major ob-
stacle in combating influenza is the rapid evolution of the
virus, rendering the host Ab response ineffective. Seasonal influ-
enza virus vaccines are therefore strain specific, do not protect well
against drifted viruses from the same hemagglutinin (HA) subtype,
and offer no protection against infection with heterologous influ-
enza viruses from different HA subtypes. Furthermore, pandemic
influenza can arise at any time, originating from either group 1 or 2
avian influenza A viruses (IAV) and can cause devastating mor-
tality. Therefore, a broadly protective influenza A vaccine (BPIV),
which could protect against both group 1 and 2 viruses, would be a
great advance in preventing seasonal infection and reducing
mortality from pandemic influenza (1).
Signal Minus FLU (S-FLU) is a replication-incompetent influ-
enza virus, candidate BPIV, and is limited to a single cycle of
replication (2) through inactivation of the HA signal sequence (3).
Functional HA protein, which is required to form infectious virus
particles, is provided in trans from a transfected cell line by
pseudotyping, and the S-FLU vaccine virus can therefore infect
the host but cannot replicate. All of the conserved viral core
proteins are expressed in the cytosol of S-FLU–infected cells for
optimal Ag presentation to T lymphocytes (4). S-FLU induces a
strong cross-reactive T cell response in the lung to the conserved
core proteins, a specific Ab response to the expressed neuramin-
idase (NA), but a minimal Ab response to the HA coating the
particle when administered to the respiratory tract. Immunization
of mice with H1N1 or H5N1 S-FLU results in a high degree of
protection against the homologous and heterologous H1N1, H6N1
(group 1), H3N2, and H7N9 (group 2) viruses, with moderate
protection against distinct (heterologous) H5N1 (3, 5). Similarly,
in ferrets, immunization with H1N1 or H5N1 S-FLU significantly
reduced replication of H1N1, H6N1, H5N1 (group 1), and H7N9
(group 2) viruses in the lung. In pigs, immunization with H1N1 or
H5N1 S-FLU reduced the viral load in nasal swabs and lungs
following challenge with a swine H1N1pdm09 isolate (6).
Because S-FLU can neither replicate nor donate its HA sequence
to other influenza strains if administered to infected individuals, it
should be safe. For this reason and because immunization via the
lower respiratory tract has been shown to be a highly effective
means of immunizing against influenza, in all experiments with
S-FLU, the vaccine was administered either intranasally to mice
and ferrets or intranasally, intratracheally, or by aerosol in pigs. Our
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results show also that targeting the lower respiratory tract by
aerosol in pigs is more effective than intratracheal or intranasal
immunization in preventing severe disease (6). The reason for this
may be that local immunization induces lung tissue-resident
memory T cells (TRM), which have been shown to be important
in cross-protective immunity against influenza infection (7–10).
Most work on TRM has been performed in mice and the TRM
defined as inaccessible to intravenously administered anti–T cell
Ab (11). TRM identified in this way are an activated, dividing
population capable of responding rapidly to Ag by further cell
division in situ in mice. However, there are very few data on TRM
in large animals.
To further assess whether S-FLU vaccines could protect from a
completely heterosubtypic challenge, in which the HA and NA of
the vaccine and challenge viruses belonged to different genetic
groups, we have tested the protective efficacy of an S-FLU coated
in contemporary human H3N2 (group 2) glycoproteins against
challenge with an H1N1pdm09 (group 1) virus in both pigs and
ferrets.
Materials and Methods
Vaccines and influenza challenge virus
The design and production of pdmH1N1 S-FLU [eGFP*/N1(Eng195)].H1
(Eng/195/2009) has been described previously (3, 5). We made a new
H3N2 S-FLU [eGFP*/N2(3217)].H3/SW/9725293/2013 (encoding N2
from A/Victoria/361/2011 from the vaccine strain 3217 and coated in H3
from A/Switzerland/9725293/2013) at 1.52 3 108/ml 50% tissue culture
infectious doses (TCID50) (95% CI 1.13 to 2.05 3 10
8/ml). The internal
protein gene segments were from influenza A/Puerto Rico/8/34 (H1N1).
In the ferret studies, a live attenuated influenza A/Switzerland/9715293/
2013 cold-adapted (ca) vaccine on the influenza A/Ann Arbor/6/60 ca
backbone was included as a comparator, and a group of mock-immunized
control animals received Leibovitz 15 (L-15) media. Influenza A/California/
07/2009 (H1N1pdm09) and A/Switzerland/9715293/2013 (H3N2) viruses
were used for challenge infection.
The pig isolate of A/swine/England/1353/09pdmH1N1 (1353/
09pdmH1N1) was used for challenge infection in pigs. The homologous
vaccine consisted of the identical b-propiolactone inactivated 1353/
09pdmH1N1 with TS6 adjuvant. TS6 adjuvant was kindly provided by
Dr. Catherine Charreyre (Merial/Boehringer Ingelheim). It contains an oily
phase (comprising sorbitan monooleate, sorbitan trioleate, paraffin oil, and
sodium mercurothiolate) and an aqueous phase of monopotassium and
disodium phosphate.
Aerosol characterization
We first established that passage through the Aerogen Solo vibrating mesh
nebulizer (Aerogen, Dangan, Galway, Ireland) did not significantly reduce
the titer of S-FLU. The cell supernatant containing S-FLU in viral growth
medium (DMEM/0.1% BSA/10 mm HEPES pH 7) was passed through a
0.22 mm filter then aerosolized using the nebulizer, captured, and con-
densed. The effect of nebulization on the infectious titer of S-FLU was
measured on three different batches of S-FLU coated in three different
HAs by comparison of quadruplicate measurements of the means of the
number of doubling dilutions (i.e., Log2 of the dilution factor) giving 50%
infection of MDCK-SIAT cells (calculated by linear interpolation) pre- and
postnebulization by an unpaired t test (Prism v7.0). H5 (A/Vietnam/1203/
2004) 20.2938 (95% CI: 20.5059 to 20.08161, p = 0.0147) = 18.4%
reduction; H7 (A/Netherlands/219/2003) 20.2067 (95% CI: 20.5808 to
0.1674, p = 0.225) = 13.3% reduction; H3 (A/Victoria/361/2011) 2
0.04246 (95% CI: 20.2699 to 0.185, p = 0.664) = 2.9% reduction. Al-
though the 18.4% reduction in the titer of the H5 S-FLU after nebulization
was statistically significant, the minimal effects on the H7 and H3 batches
did not reach statistical significance. We regard these small effects of the
vibrating mesh nebulizer on infectious titer of S-FLU as not biologically
significant.
We then assessed the aerosol droplet size distribution using a cascade
impactor (Next Generation Impactor; Copley Scientific) at 15 l/min
vacuum flow rate. A known quantity of virus (2.13–3.39 3 109 CID50
in 4 ml viral growth medium) was passed into the impactor and subse-
quently harvested from each of the impactor stages, which fractionate the
aerosol droplets by size. In three replicates, the mean aerodynamic size
of the aerosol droplets was 1.953 mm with a geometric SD of 1.795. The
fine particle fraction, which is the fraction of the aerosol produced with a
droplet size ,5 mm, was 92.34%, indicating that the aerosol produced
was highly respirable.
Animals and immunizations
Pigs. All experiments were approved by the ethical review processes at the
Pirbright Institute and Animal and Plant Health Agency and conducted
according to the U.K. Government Animal (Scientific Procedures) Act
1986. Both institutes conform to Animal Research: Reporting of In Vivo
Experiments guidelines. Eighteen, 5–6-wk-old landrace cross female
pigs were obtained from a commercial high-health status herd (average
weight of 10 kg at the beginning of the experiment). Pigs were screened for
absence of influenza A infection by matrix gene real-time RT-PCR and for
Ab-free status by hemagglutination inhibition using four swine influenza
virus Ags. Pigs were randomly divided into three groups of six and im-
munized as follows: 1) control unimmunized, 2) Homologous (1353/
09pdmH1N1) vaccine containing 2048 hemagglutination units adminis-
tered i.m. in 1 ml, and 3) H3N2 S-FLU administered by aerosol delivering
∼1.5 3 108 TCID50 in 1 ml. The animals received an identical booster
immunization 21 d later. S-FLU was administered using an Aerogen Solo
nebulizer attached to a custom-made mask held over the animal’s nose and
mouth (Supplemental Fig. 1) following sedation.
For logistical reasons, two IAV challenges were performed, with half of
the animals challenged at 28 d postboost (dpb) and the remainder at 30 dpb.
Animals were challenged intranasally with 1.53 106 PFU per pig of 1353/
09pdmH1N1. Two milliliters were administered to each nostril using a
mucosal atomization device, MAD300 (Wolfe Tory Medical). As the
analysis of samples from pigs challenged at days 28 and 30 did not show
any significant differences, for simplicity in presentation, the results of the
assays carried out on pigs challenged on both days have been amalgamated
in all figures.
Ferrets. Four- to six-month-old female ferrets that were seronegative by
hemagglutination inhibition assay to circulating influenza A H1N1pdm09
and H3N2 viruses were purchased from Triple F Farms, Sayre, PA. The
ferret experiments were conducted in animal BSL2 laboratories at
the National Institutes of Health in compliance with the guidelines of the
Institutional Animal Care and Use Committee. Ferrets were lightly
anesthetized with isoflurane and immunized intranasally with two doses
of 107 TCID50 in 0.5 ml of A/Switzerland/9715293/2013 S-FLU, 10
7
TCID50 in 0.5 ml of A/Switzerland/9715293/2013 ca, or 0.5 ml of L-15
21 d apart. The ferrets were challenged with 106 TCID50 in 1 ml of in-
fluenza A/California/07/2009 (H1N1pdm09) or A/Switzerland/9715293/
2013 (H3N2) virus.
Pathological and histopathological examination of pig lungs
Animals were humanely killed 5 d postchallenge (dpc). At post mortem, the
lungs were removed, and digital photographs were taken of the dorsal and
ventral aspects. Macroscopic pathology was scored blind, as previously
reported (12). Five lung tissue samples per animal from the right lung (two
pieces from the apical, one from the medial, one from the diaphragmatic,
and one from the accessory lobe) were collected into 10% neutral buffered
formalin for routine histological processing at the University of Surrey.
Formalin-fixed tissues were paraffin wax–embedded, and 4-mm sections
were cut and routinely stained with H&E. Immunohistochemical staining
of influenza virus nucleoproteins (NP) was performed in 4-mm tissue
sections as previously described (13). Histopathological changes in the
stained lung tissue sections were scored by a veterinary pathologist blinded
to the treatment group. Lung histopathology was scored using five pa-
rameters (necrosis of the bronchiolar epithelium, airway inflammation,
perivascular/bronchiolar cuffing, alveolar exudates, and septal inflamma-
tion) scored on a five-point scale of 0 to 4 and then summed to give a total
slide score ranging from 0 to 20 and a total animal score from 0 to 100 (6).
The Iowa system includes both histological lesions and immunohisto-
chemical staining for NP (14).
Tissue sample processing
Pigs. Four nasal swabs (two per nostril) were taken daily after the
challenge. Serum and heparin anticoagulated blood samples were col-
lected at the start of the study (prior to immunization) and at days 7, 14,
21, 28, 35, 42, and 49 after the first immunization. Bronchoalveolar lavage
(BAL) and tracheobronchial lymph nodes (TBLN) were processed as
previously described (6). Medial and diaphragmatic lung cells were
dissociated into a single-cell suspension with the gentleMACS Octo
Dissociator (Miltenyi Biotec), using C tubes (Miltenyi Biotec) with 5 ml
of serum-free RPMI 1640 containing collagenase and DNAse (Sigma-
Aldrich). Following dissociation, the tubes were incubated at 37˚C for
20 min, the resulting suspension was mashed through a tea strainer using
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complete RPMI 1640, and the single-cell suspension was filtered twice
using a 100 mm cell strainer, washed, and RBCs were lysed. Cells were
washed and cryopreserved.
Ferrets. Four ferrets from each group were sacrificed at 2 and 4 dpc, and
their lungs and nasal turbinates (NT) were harvested. Harvested tissues were
homogenized in L-15 medium at 10% (w/v) for lung or 5% (w/v) for NT
samples clarified by centrifugation at 2500 rpm for 10 min.
Transmission studies in ferrets
We performed airborne transmission studies using a caging system pre-
viously described (15). Briefly, four adult ferrets obtained from Triple F
Farms that were seronegative by hemagglutination inhibition to circulating
H1N1pdm09 and H3N2 viruses were anesthetized by i.m. injection of a
ketamine-xylazine mixture prior to intranasal immunization with two
doses of H3N2 S-FLU or with L-15 medium alone (mock immunized).
Twenty-one days after the second dose, ferrets were challenged with 106
TCID50 of A/California/07/2009 virus. Challenged ferrets were placed into
the section of the cage closest to the air inlet the day of challenge. One day
later, a naive ferret was placed into the cage on the other side of the di-
vider. Environmental conditions inside the laboratory were monitored daily
and were consistently 19 6 0.3˚C and 60 6 2.2% relative humidity. The
transmission experiments were conducted in the same room to minimize
any effects of caging and airflow differences on aerobiology. The naive
ferret was always handled before the infected ferret. Animals were care-
fully handled during nasal wash collections and husbandry to ensure no
FIGURE 1. Viral load in nasal swabs. Pigs were immunized twice 21 d apart with either homologous inactivated vaccine by the i.m. route (Homologous)
or H3N2 S-FLU by aerosol (S-FLU). Controls were unimmunized pigs. Animals were challenged with 1353/09pdmH1N1 28 or 30 d after the boost. Nasal
swabs were taken at 0, 1, 2, 3, 4, and 5 dpc, and pigs were sacrificed at 5 dpc. As the analysis of samples from pigs challenged at days 28 and 30 did not
show any significant differences, for simplicity in presentation, the results of the assays carried out on pigs challenged on both days have been amalgamated
in this and other figures. Viral titers in the nasal swabs (A) and BAL (B) were determined by plaque assay. The mean value for shedding for each group is
shown over the 5 d (A). Each data point represents an individual within the indicated group, and bars represent the mean (B). Asterisks denote significant
differences between the indicated groups and controls. *p, 0.05, **p , 0.01, determined using one-way ANOVAwith Dunn test for multiple comparison.
FIGURE 2. Gross and histopathology. Pigs were immu-
nized twice 21 d apart with either homologous inactivated
vaccine i.m. (Homologous) or H3N2 S-FLU by aerosol
(S-FLU). Controls were unimmunized animals. Animals
were challenged with 1353/09pdmH1N1 on 28 or 30 dpb.
Animals were sacrificed at 5 dpc, and lungs were scored for
appearance of gross pathology (A) and histopathological
lesions (B). Each data point represents an individual within
the indicated group, and bars represent the mean. (C) Gross
pathology, histopathology (H&E), and immunohistochemi-
cal NP staining of representative lungs for each group are
shown. Areas of purple-red consolidation (green arrows) are
present in lungs from infected groups. Microscopic lesions
include alveolar septal inflammation, peribronchiolar in-
flammatory cell cuffing, and necrotizing/suppurative bron-
chiolitis with presence of NP Ag in bronchiolar epithelial
cells and inflammatory cells (black arrows). Original mag-
nification 3400. Asterisks denote significant differences
from the control group. **p , 0.01, ***p , 0.005, deter-
mined using one-way ANOVA with Dunn test for multiple
comparisons.
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direct contact occurred between the ferrets. Nasal washes were collected
every other day for 14 d and analyzed for the presence and titer of in-
fectious viruses and expressed as TCID50 per ml. On day 14 postinfection,
blood was collected from each animal, and serology was performed by
hemagglutination inhibition and microneutralization assays.
Virus titration. Viral titers in nasal swabs and BAL from pigs were de-
termined by plaque assay on MDCK cells as previously described (6).
Clarified homogenates of ferret tissues were titrated on MDCK cell
monolayers, and virus titers were calculated by the Reed and Muench
method and expressed as log10 TCID50 per g.
Microneutralization assay.Neutralizing Ab titers in serum were determined
as previously described (3, 16)
IFN-g ELISPOT assay. Frequencies of IFN-g–secreting pig PBMC and BAL
cells were determined by ELISPOT assay using fresh or cryopreserved cells
(6). Cells were stimulated with either 1 3 106 PFU live MDCK-grown1353/
09pdmH1N1, 13 105 TCID50 H3N2 S-FLU, medium control, or 10 mg/ml Con
A (Sigma-Aldrich). Results were expressed as number of IFN-g–producing cells
per 106 cells after subtraction of the average number of IFN-g+ cells in medium
control wells.
Flow cytometry. Cryopreserved mononuclear cells from blood, TBLN,
BAL, spleen, and lung were thawed and stimulated for 12 h at 37˚C with
either 1 3 106 PFU live MDCK-grown strain 1353/09pdmH1N1 or 1 3 106
TCID50 H3N2 S-FLU or MDCK mock supernatant as control. GolgiPlug (BD
Biosciences) was added for a further 4 h before intracellular cytokine staining.
Cells were stained for surface markers with CD3ε-AF647 BB23-8E6-8C8,
CD4 clone 74-12-4 PerCpCy5.5, CD8a-FITC 76-2-11 (BD Biosciences),
and Near-Infrared Fixable LIVE/DEAD stain (Invitrogen). Cells were per-
meabilized using Cytofix/Cytoperm (BD Biosciences) before intracellular
FIGURE 3. Ab and IFN-g ELISPOT responses in pigs. Pigs were immunized twice 21 d apart with either homologous inactivated vaccine i.m. (Homol-
ogous) or S-FLU by aerosol (S-FLU). Animals were challenged with 1353/09pdmH1N1 on 28 or 30 d after the boost. (A) Individual 50% inhibition titers in the
serum at 7 dpb, 28 dpb, just before the challenge, and 5 dpc. Numbers of IFN-g SFC in PBMC (B) and BAL (C) were determined by ELISPOT following
stimulation with the challenge virus 1353/09pdmH1N1 or H3N2 S-FLU in vitro. Results for 1353/09pdmH1N1 and H3N2 S-FLU stimulation were expressed as
number of IFN-g–producing SFC per 106 cells after subtraction of the average number of IFN-g+ cells in medium control wells. Cells cultured in medium alone
are also shown to indicate the background obtained. Each data point represents an individual within the indicated group. Asterisks denote significant differences
from the control group. *p , 0.05, ***p , 0.005, determined using two-way ANOVA with Dunnett test for multiple comparisons.
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staining with IFN-g PE P2G10 (BD Biosciences) and cross-reactive anti-
human TNF-a-AF650 Mab11 (BioLegend). Samples were fixed in 1% para-
formaldehyde before analysis using an LSRFortessa (BD Biosciences). Data
were analyzed using FlowJo v10 (Tree Star).
Lung TRM. Before sacrifice, three animals from each group were infused
i.v. with 10 ml of 3.24 mg/ml purified CD3 Ab (clone PPT3) and sacrificed
10 min later. Lymphocytes were isolated and stained ex vivo with anti-mouse
Ig-FITC (SouthernBiotech), which labels the circulating intravascular cells.
FIGURE 4. Cytokine-producing cells in pig TBLN, BAL, and lung tissues. Flow cytometry was used to quantitate the frequency of IFN-gN, IFN-g TNF-a–,
and TNF-a–positive cells within CD8hi (A) and CD4+CD8+ (B) cells at 5 dpc. Cells were stimulated with either challenge virus 1353/09pdmH1N1 or H3N2 S-
FLU. Each data point represents an individual within the indicated group. Asterisks denote significant differences from the control group. *p , 0.05, **p ,
0.01, ***p , 0.005, determined using two-way ANOVA with Dunnett test for multiple comparisons.
The Journal of Immunology 5
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The cells are washed, and normal mouse serum is then added to block any
remaining binding capacity of the anti–Ig-FITC. The cells are then washed
again and incubated with CD3 Ab labeled with PeCy5 (Abcam). This will bind
unsaturated sites of the circulating cells, which are therefore double labeled, as
well as all the sites on the TRM that are not accessible to the CD3 Ab, given i.v.
TRM is therefore single labeled with PeCy5.
To allow intracytoplasmic staining of TRM, the i.v. CD3 was detected
with goat anti-mouse IgG BV421 (BioLegend) and blocked using normal
mouse serum as above. Surface markers used were CD3ε-biotin PPT3
(Abcam), CD4 clone 74-12-4 PerCpCy5.5, CD8a-FITC 76-2-11 (all BD
Biosciences), and Near-Infrared Fixable LIVE/DEAD stain (Invitrogen).
Biotinylated CD3 was visualized with a streptavidin AF647 (BioLegend).
Cells were permeabilized using Cytofix/Cytoperm before intracellular
staining with IFN-g PE P2G10 (BD Biosciences) and cross-reactive anti-
human TNF-a-AF650 Mab11 (BioLegend). Samples were fixed in 1%
paraformaldehyde before analysis using an LSRFortessa.
Statistical analysis.One-way or two-way ANOVAwith Dunnett posttest for
multiple comparisons were used to compare immunized groups to the
control group, and analysis was performed using GraphPad Prism 6.
Results
Viral load and lung pathology in pigs
Groups of six pigs were immunized twice 3 wk apart with an
inactivated virus with adjuvant i.m. (Homologous inactivated) or
with H3N2 S-FLU by aerosol (S-FLU). The control group was
unimmunized (control). Aerosol immunization was carried out
using a purpose-built mask and Aerogen Solo nebulizer that
allowed efficient vaccine delivery in ,5 min to the sedated ani-
mals after we had established that the nebulizer did not affect the
titer of the S-FLU vaccines and provided a droplet size appropriate
for delivery to the lower respiratory tract (Supplemental Fig. 1).
Four weeks after the second immunization, the animals were
challenged intranasally with swine isolate of pandemic H1N1 A/
Sw/Eng/1353/09 (1353/09pdmH1N1) virus and sacrificed 5 dpc.
The pigs immunized with the Homologous inactivated vaccine
showed the greatest and statistically significant reduction of challenge
virus in the nasal swabs at 1, 2, 3, 4, and 5 dpc (Fig. 1A). S-FLU did
not reduce viral shedding in nasal swabs significantly at any day
postchallenge (Fig. 1A), although two out of the six S-FLU–immu-
nized animals did not shed virus on day 5. No virus was detected in
the BAL of the Homologous inactivated vaccine group, and although
S-FLU reduced viral load in the BAL, with no virus in three animals,
this reduction was not statistically significant (Fig. 1B).
Following challenge, the unimmunized animals developed
typical gross lesions of influenza virus infection (17). Histopa-
thology showed lesions consisting of severe multifocal interstitial
pneumonia, attenuation of the bronchial and bronchiolar epithe-
lium, presence of inflammatory infiltrates within the interalveolar
septa and the alveolar lumen, and edema. Immunohistochemical
detection of influenza virus NP showed many positive cells within
the endothelium of bronchi and bronchioles (Fig. 2).
Animals immunized with the Homologous inactivated vaccine
showed very few gross pathological lesions. Histologically, only a
few lung sections showed mild interstitial pneumonia and necrosis
of the bronchial and bronchiolar epithelium. Virus NP immuno-
staining was restricted to very few inflammatory cells within the
interalveolar septa. The S-FLU–immunized animals showed small
areas of gross pathology. Histopathology showed mild to moderate
interstitial pneumonia, edema, and epithelial necrosis within the
bronchi and bronchioles. Few bronchiolar epithelial and inflam-
matory interstitial cells exhibited NP immunostaining (Fig. 2).
These results indicated that immunization of pigs with a group 2
H3N2 S-FLU significantly reduced gross and histopathology but
did not significantly reduce the viral load in nasal swabs and BAL
after heterologous challenge with group 1 H1N1pdm09 virus.
Ab and IFN-g ELISPOT responses in pigs
We determined the Ab response in pigs using microneutralization
assay. Sera from the Homologous inactivated vaccine group had
neutralizing Ab, with mean inhibitory titers of 1:2291 at 7 dpb,
1:1166 at 28 dpb, and at 1:1801 at 5 dpc. This indicates that the
Homologous inactivated vaccine was successfully delivered and
induced anti-1353/09pdmH1N1 neutralizing Abs as expected. Also
as expected, no neutralizing Ab to the H1N1 virus was detected in
the S-FLU or in the unimmunized controls (Fig. 3A).
We determined influenza-specific T cell responses in PBMC in
pigs by IFN-g ELISPOT at 7 and 28 dpb, just before the challenge,
and at the time of sacrifice 5 dpc. PBMC were stimulated with
either the challenge virus 1353/09pdmH1N1 or with H3N2
S-FLU. Both homologous inactivated vaccine and S-FLU–
immunized animals showed a virus-specific response to the challenge
virus at 7 dpb, which was higher in the homologous inactivated
group (mean 91 for the homologous inactivated vaccine and 27 for
S-FLU spot-forming cells [SFC] per 106 cells). The response to
stimulation with H3N2 S-FLU was minimal (mean 39 SFC in
homologous inactivated and 17 SFC in S-FLU group). At 28 dpb,
just before the challenge, the response was undetectable in any of
the groups. At 5 dpc, the S-FLU–immunized animals showed the
strongest response to both 1353/09pdmH1N1 and H3N2 S-FLU
stimulation (mean 665 and 1211 SFC per 106 cells for homolo-
gous inactivated vaccine and S-FLU groups, respectively)
(Fig. 3B). The reduced response in the homologous inactivated
vaccine group was most likely due to the lack of Ag stimulation
because of the greatly reduced influenza A viral load in these
animals.
The response in the BAL showed a similar trend. However, the
detectable response was apparently much weaker (∼30 SFC per
106 cells for S-FLU) because of the low percentage of T cells in
BAL. There was also a high medium control background most
likely because of the presence of many activated cells in the BAL
(Fig. 3C). These data show that, as expected, the Homologous
inactivated vaccine induced a strong Ab response, whereas in
contrast, S-FLU did not induce detectable neutralizing Ab, but
these animals had the highest number of IFN-g–producing cells
following stimulation with either 1353/09pdmH1N1 or H3N2 S-
FLU postchallenge.
Analysis of cytokine-producing cells
To dissect which cells produce cytokines, we performed intra-
cellular staining for IFN-g and TNF-a combined with surface
staining for CD4, CD8, and CD4CD8 cell subsets. The latter are
the activated memory CD4 cells in pigs (18). To analyze local
immune responses, TBLN, lung, and BAL cells were stimulated
with either the challenge virus 1353/09pdmH1N1 or with H3N2
S-FLU. S-FLU immunization induced the highest proportion of
double IFN-g TNF-a cytokine-producing CD8 cells in lymph
node, BAL, and lung, followed by single IFN-g or single TNF-a
producers in the TBLN (Fig. 4A). Similarly, the S-FLU–
immunized animals had the highest proportion of CD4CD8 cells
producing single IFN-g and double IFN-g TNF-a cytokines in the
BAL and lung (Fig 4B). A statistically significant proportion of
single TNF-a producers was observed in TBLN CD8 and CD4CD8
cells. The CD4 response was negligible in all tissues and is not
shown. In contrast to the local tissues, systemic responses analyzed
in PBMC and spleen showed lower proportions of CD8 or CD4CD8
Ag-specific cells (data not shown).
In summary, the S-FLU immunization induced a strong local
lung response to IAV and S-FLU. The high frequency of these
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single and double IFN-g and TNF-a producers may account for
the protective efficacy of local immunization.
Tissue-resident memory cells
Because we have shown that aerosol immunization with H3N2
S-FLU induced a strong local immune response, we wished to
establish whether the responding cells were part of the TRM
population. To distinguish TRM in the lungs of pigs from circu-
lating cells present in the vasculature of the tissue, we adminis-
tered CD3 mAb i.v. 10 min before sacrificing the animal. After
sacrifice, the lymphocytes were isolated and stained ex vivo with
anti-mouse IgG-FITC and with the same clone of CD3 directly
labeled with PeCy5. As the infused CD3 does not saturate all CD3
sites, blood, spleen, and some lung tissue T cells are double
positive (intravascular cells) (Fig. 5A). In contrast, most BAL and
some lung tissue cells are only CD3PeCy5 positive, indicating that
they are inaccessible to the Ab in the blood (TRM). Lymph nodes
were inaccessible to the infused CD3 Ab, as has been shown to be
the case by others (19). There was no difference in the proportions
of TRM and intravascular cells in the immunized and control pigs
(data not shown). A similar pattern has been observed in more
than 20 animals from other studies.
As BAL is 90% stained only by the ex vivo CD3PeCy5, whereas
the blood and spleen are double labeled, this indicates that most
BAL cells are part of the blood-inaccessible pool of TRM. Because
BAL gives a strong Ag-specific response, we can conclude that
FIGURE 5. Porcine lung TRM. (A) Before sacrifice, three pigs from each group were infused i.v. with CD3 Ab and sacrificed 10 min later. Lymphocytes
were isolated and stained ex vivo with anti-mouse Ig-FITC, and the same CD3 Ab labeled with PeCy5. As the infused CD3 does not saturate all CD3 sites,
blood, spleen, and some lung tissue T cells are double positive (intravascular cells). BAL and some of lung cells are unstained by intravascular Ab (TRM).
(B) Lower panels show IFN-g and TNF-a production by intravascular and TRM CD8 and CD4CD8 cells in H3N2 S-FLU–immunized animals after in vitro
stimulation with either challenge virus 1353/09pdmH1N1 or H3N2 S-FLU.
The Journal of Immunology 7
 by guest on June 6, 2018
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
S-FLU is inducing lung TRM. Our staining in lung indicates that a
proportion of lung T cells (39%) are inaccessible to i.v. CD3 Ab
and are therefore also part of the TRM population. The TRM in the
three S-FLU–immunized animals treated with i.v. Ab had a higher
proportion of Ag-specific cells producing IFN-g and TNF-a than
the lung intravascular population (Fig. 5B) following stimulation
with either the challenge virus 1353/09pdmH1N1 or with H3N2
S-FLU. The comparison between intravascular and TRM in the
Homologous inactivated and control groups is unreliable because
there were few responding cells and therefore very few events in
the gated populations (data not shown). These results demonstrate
that aerosol immunization with H3N2 S-FLU induces a large lung
TRM population.
Evaluation of the H3N2 S-FLU vaccine in ferrets
We next determined the protective efficacy of the same batch of H3
S-FLU in ferrets, using as a positive control live attenuated virus
H3N2 ca, as we have previously used similar ca viruses for this
purpose in ferrets (5). We also immunized intranasally rather than
by aerosol as, in anesthetized small animals, intranasal adminis-
tration has been shown to reach the lungs (20, 21). Groups of 12
ferrets were immunized intranasally twice with H3N2 S-FLU or
H3N2 ca, and 12 ferrets were mock-vaccinated. Three weeks later,
half the animals in each group (n = 6 per group) were challenged
with intranasally delivered homologous wild-type (wt) influenza
A/Switzerland/9715293/2013 (H3N2) and the other half with a
heterologous influenza A/California/07/2009 (H1N1pdm09) virus.
On days 2 and 4 postchallenge, three ferrets in each group were
sacrificed, and virus titers in lungs and NT were assessed. The
homologous wt H3N2 virus did not replicate in the lower respi-
ratory tract of mock-immunized (or vaccinated) ferrets (Fig. 6A),
so the efficacy of the vaccines in protecting against pulmonary
virus replication could not be assessed. However, wt H3N2 virus
replicated to a moderately high titer (mean 104.95TCID50/g) in the
NT at 4 dpc, and both vaccines prevented replication of the
challenge virus in the NT (p , 0.05).
The H1N1pdm09 virus that was used for heterosubtypic chal-
lenge replicated to a high titer in the NT (mean 107.8 and 106.5
TCID50/g at 2 and 4 dpc, respectively) and to a modest-to-
moderate titer (mean 102.9 and 104.3 TCID50/g at 2 and 4 dpc)
in the lungs (Fig. 6B). Both the S-FLU and ca vaccine viruses
provided modest reduction (104.6 and 103.4 TCID50/g, respec-
tively) in H1N1pdm09 titers in the NT at 2 dpc and further re-
duction (102.3 and 102.8, respectively) at 4 dpc, although only the
S-FLU group on day 4 was significantly different from the mock-
immunized group (p , 0.05). A statistically significant reduction
in lung virus titers was observed on day 4 postchallenge but only
in animals that had received the H3N2 ca virus vaccine
(p = 0.002).
Effect of H3N2 S-FLU vaccine on transmission in ferrets
We next determined whether immunization with H3N2 S-FLU
would prevent transmission of the heterologous H1N1pdm09
challenge virus. Four ferrets each were vaccinated intranasally with
two doses of H3N2 S-FLU, and four ferrets were mock vaccinated;
the ferrets were challenged intranasally with influenza A/
California/07/2009 (H1N1pdm09) 21 d after the second dose of
vaccine and were placed in transmission cages. The following day,
an unvaccinated naive ferret was introduced adjacent to each in-
fected ferret. The experimentally infected and respiratory contact
ferrets were followed with nasal washes and serology to determine
whether the H1N1pdm09 virus transmits by the respiratory route
from experimentally infected to airborne contact ferrets. One ferret
each in the mock-immunized and H3N2 S-FLU–vaccinated groups
reached their humane endpoints 9 dpc from an intercurrent in-
fection in the animal house. Unfortunately, we were not able to
identify the etiology of the intercurrent infection that caused
weight loss in ferrets. None of the ferrets were found dead. They
were euthanized in accordance with our approved animal study
protocol because of weight loss. The virus inoculum was not
contaminated with bacteria, and the virus dose was confirmed to
be correct.
All four of the mock-immunized ferrets were infected with
H1N1pdm09 and transmitted to their airborne contacts (Fig. 7).
Infection with and transmission of the H1N1pdm09 virus was
greatly reduced in frequency and viral load in the animals that
were immunized with H3N2 S-FLU vaccine and their airborne
contacts. Challenge virus was detected in nasal washes of one of
three H3N2 S-FLU–vaccinated ferrets, but all three seroconverted.
Virus was detected in two of three of the corresponding air-
borne contact animals at a low titer for a limited period, but neither
of the contact animals seroconverted. Thus, the H3N2 S-FLU
FIGURE 6. Virus replication in respiratory tissues of ferrets immunized
and challenged with homologous or heterologous virus. Ferrets were
lightly anesthetized with isoflurane and immunized intranasally with two
doses of 107 TCID50 in 0.5 ml of A/Switzerland/9715293/2013 S-FLU, 10
7
TCID50 in 0.5 ml of A/Switzerland/9715293/2013 ca, or 0.5 ml of L-15
21 d apart. The ferrets were challenged with 106 TCID50 in 1 ml of in-
fluenza A/Switzerland/9715293/2013 (H3N2) (A) or A/California/07/2009
(H1N1pdm09) (B) virus. Ferrets from each group were sacrificed on days 2
(D2) and 4 (D4) postinfection, and viral load in their lungs and NT was
determined and expressed as log10 TCID50 per g. Dotted lines indicate the
limit of detection for each assay. Horizontal bars represent mean titers, and
symbols represent titers from individual ferrets. *p , 0.05, **p , 0.002.
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vaccine severely restricted shedding of the H1N1pdm09 challenge
virus, although infection did occur. Although airborne transmis-
sion occurred, the intensity of the transmitted infection to airborne
contact ferrets was markedly reduced with low titer, short duration
viral shedding, and no seroconversion in airborne contact ferrets.
Discussion
There is strong epidemiological evidence for an association be-
tween a cross-reactive T cell response and heterologous protection
between group 1 and 2 IAV in humans (22, 23). In the first of these
studies, the association with the T cell response was predomi-
nantly with reduced fever and symptoms (22), whereas in the
second, the T cell response to NP was associated with reduced
viral shedding in symptomatic volunteers (23). In these studies,
the correlation was with the T cell response in peripheral blood
that had likely been induced by prior natural infection. This evi-
dence, combined with a long history of animal studies demon-
strating the protective effect of T cells induced by live influenza
virus infection (24), provides the rationale for developing a safe
and BPIV that induces a strong T cell response in the human lung.
In this study, we compared the outcome of heterosubtypic influ-
enza virus challenge after S-FLU vaccination in both pigs and
ferrets. H3N2 S-FLU immunization of pigs had a minimal effect
on H1N1pdm09 replication after challenge but a significant effect
on pathology. By contrast, in the ferret, the same vaccine prepa-
ration induced sterile immunity to the matched H3N2 challenge
and reduced replication and aerosol transmission to naive recipi-
ents following H1N1pdm09 challenge. Our results also show that
aerosol delivery of H3N2 S-FLU vaccine is safe and induced
strong local lung immune responses and TRM in BAL and lung
tissues of pigs.
In earlier experiments in ferrets and mice, in which there was a
complete mismatch between the immunizing H1N1 or H5N1
(group 1) S-FLU and challenge H3N2 and H7N9 (group 2), we
observed a significant reduction in replication of the infectious
challenge virus (3, 5). In the current study, we used another
mismatched immunization and challenge combination and con-
firmed a significant effect on replication of the challenge virus in
ferrets but not pigs. A possible reason for the difference between
pigs and ferrets might be that the H3N2 S-FLU used in this study
is coated with the clade 3C.3a H3 HA. This H3 is exquisitely
specific for a2–6 sialic acid but has low affinity (25) and, although
the pig respiratory tract expresses both a2–3 and 2–6 (26), it is
possible that the binding of H3 to the pig respiratory tract is poor.
Experiments with S-FLU coated in different HAs may resolve
this. Another possibility is that, although H3N2 S-FLU induced a
strong local response against the immunizing and challenge
viruses, this was insufficient to prevent replication of the challenge
virus. We speculate that a higher dose of vaccine might be re-
quired, as earlier work in pigs immunized with attenuated influ-
enza showed a reduction in challenge virus replication despite
mismatching (27). Further work to examine whether a higher dose
of vaccine is required to fully protect the lungs of large animals
needs to be performed.
In other experiments in small animals, the effect of fully het-
erosubtypic immunization was similar to what we observe in pigs.
For example, a single-replication cycle H1N1 (group 1) BPIV
based on the partial deletion of theM2 gene (28) induced sterilizing
immunity against matched challenge and protected mice against
death from heterosubtypic H3N2 (group 2) challenge but did not
prevent viral replication in NT and lung. The protective effect was
associated with the induction of cross-reactive T cells but not Ab
and a reduced inflammatory neutrophil infiltrate in the lung. In
ferrets with partial matching of a single-cycle live attenuated vi-
rus, in which vaccine (H1N1, group 1) and challenge (H5N1,
group 1) were selected from the same genetic group, protection
was associated with the induction of cross-reactive Ab to the
conserved group 1 HA stem and the N1 NA in addition to cross-
reactive T cells, and challenge viral replication was reduced (29).
These results suggest that protective immune responses to live
attenuated or single-cycle viruses may be cumulative, and partial
matching between vaccine and challenge within the same genetic
group can add incremental protective value through the induction
of cross-reactive Abs, as strongly suggested by the epidemiology
of human infections (30). Unfortunately, the group of origin of
future pandemic or even seasonal viruses cannot be predicted.
It is increasingly evident that local immune responses and
particularly lung TRM play a major role in protection against in-
fluenza viruses in mice (9, 10, 31). Pulmonary TRM in the BAL
and lung tissues have greater protective capacity than circulating
memory CD8 T cells (9, 32, 33). BAL TRM are associated with
reduced symptoms and viral load in respiratory syncytial virus
infection in humans (34). To our knowledge, in this study we show
for the first time that we can distinguish TRM in pigs, as has been
shown in mice following i.v. administration of CD3 Ab. We
demonstrate that more than 90% of BAL cells are inaccessible to
FIGURE 7. Ferrets immunized with H3N2 vaccine were protected
against challenge infection with H1N1pdm09 virus, and the transmission
to naive animals was restricted. Four ferrets were vaccinated intranasally
with two doses of H3N2 S-FLU, and four ferrets were mock-vaccinated.
Twenty-one days after the second immunization, the ferrets were chal-
lenged intranasally with influenza A/California/07/2009 (H1N1pdm09),
and the ferrets were placed in transmission cages. The following day, an
unvaccinated naive ferret was introduced adjacent to each infected ferret.
Nasal washes were collected every other day for 14 d, and virus titers in
the experimentally infected and airborne contact ferrets are presented.
Each bar represents a single ferret. One ferret each in the mock-immunized
and H3N2 S-FLU–vaccinated group reached their humane endpoints 9 dpc
from an intercurrent infection in the animal house (etiology not identified).
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intravascular Ab as well as a proportion of the lung tissue cells.
Aerosol immunization with H3N2 S-FLU induces a strong im-
mune response of these cells, which may not reduce viral repli-
cation, but may be able to induce a beneficial reduction in local
inflammation through the release of immuno-modulating cyto-
kines (35–37).
In summary, our data show that the same vaccine has different
protective efficacy in pigs and ferrets. In the absence of Ab, lung
T cell immunity can consistently reduce disease severity but does
not always abolish viral replication. We suggest that candidate
BPIV should be tested in more than one species. The pig maybe a
relevant large animal model because it is a natural host for influenza
viruses and has very similar respiratory anatomy to humans.
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